Disease Resurgence, Production Capability Issues and Safety Concerns in the Context of an Aging Population: Is There a Need for a New Yellow Fever Vaccine?

Tomashek, Kay M.; Challberg, Mark D.; Nayak, Seema; Schiltz, Helen

doi:10.3390/vaccines7040179

Cited by 15 publications

(29 citation statements)

References 119 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Integration of the scattered data on epidemiological, environmental, clinical and basic research on developmental biology, inflammatory diseases, cancer and vaccine sciences, treatment options are outlined below 1‐14,17,24,50,71,82,86,93,119,120,128,136,150‐153,155,156,176,177,182‐185,203‐207,209‐218,220 , , , :…”

Section: Twentieth Century Medicine: Shifting Disease Categories To Imentioning

confidence: 99%

Retracted: Deceptology in cancer and vaccine sciences: Seeds of immune destruction‐mini electric shocks in mitochondria: Neuroplasticity‐electrobiology of response profiles and increased induced diseases in four generations – A hypothesis

Khatami

2020

Clinical & Translational Med

View full text Add to dashboard Cite

Schematic representation of cause, exacerbation and consequence of vaccinesinduced diverse immune disorders in immune-responsive or immune-privileged tissues. It depicts that vaccination of the unborn, alter biology of trophoblastembryo-fetus-placenta and orderly growth and development affecting epithelialmesenchymal transition, proper expression of constituent-inducible receptor molecules; consequently influence immunity of newborn, infant, children and adults. Vaccine-induced impaired organ development and immunity include impaired mitochondrial function (mitophagy), tissue bioenergetics, loss of balance in Yin (tumoricidal) and Yang (tumorigenic) pathways and altered metabolic-neuronal-hormonal activities as bases for increased induced diseases in young and old.

show abstract

Section: Twentieth Century Medicine: Shifting Disease Categories To Imentioning

confidence: 99%

Retracted: Deceptology in cancer and vaccine sciences: Seeds of immune destruction‐mini electric shocks in mitochondria: Neuroplasticity‐electrobiology of response profiles and increased induced diseases in four generations – A hypothesis

Khatami

2020

Clinical & Translational Med

View full text Add to dashboard Cite

show abstract

“…YF vaccines are effective and safe in most cases; however, some adverse events (AEs) and a few rare serious adverse events (SAEs) have been reported [ 26 ]. SAEs may occur following vaccination even in individuals that produce high neutralizing antibody levels [ 27 , 28 , 29 ], leading to the hypothesis of inborn innate response failure [ 30 ].…”

Section: Introductionmentioning

confidence: 99%

Activation of an Effective Immune Response after Yellow Fever Vaccination Is Associated with the Genetic Background and Early Response of IFN-γ and CLEC5A

Azamor

Silva

Melgaço

et al. 2021

Viruses

View full text Add to dashboard Cite

The yellow fever vaccine (YF17DD) is highly effective with a single injection conferring protection for at least 10 years. The YF17DD induces polyvalent responses, with a TH1/TH2 CD4+ profile, robust T CD8+ responses, and synthesis of interferon-gamma (IFN-γ), culminating in high titers of neutralizing antibodies. Furthermore, C-type lectin domain containing 5A (CLEC5A) has been implicated in innate outcomes in other flaviviral infections. Here, we conducted a follow-up study in volunteers immunized with YF17DD, investigating the humoral response, cellular phenotypes, gene expression, and single nucleotide polymorphisms (SNPs) of IFNG and CLEC5A, to clarify the role of these factors in early response after vaccination. Activation of CLEC5A+ monocytes occurred five days after vaccination (DAV). Following, seven DAV data showed activation of CD4+ and CD8+T cells together with early positive correlations between type II IFN and genes of innate antiviral response (STAT1, STAT2, IRF7, IRF9, OAS1, and RNASEL) as well as antibody levels. Furthermore, individuals with genotypes rs2430561 AT/AA, rs2069718 AG/AA (IFNG), and rs13237944 AC/AA (CLEC5A), exhibited higher expression of IFNG and CLEC5A, respectively. Together, we demonstrated that early IFN-γ and CLEC5A responses, associated with rs2430561, rs2069718, and rs13237944 genotypes, may be key mechanisms in the long-lasting immunity elicited by YF17DD.

show abstract

“…The aforementioned issues associated with the current YFV 17D vaccines has spawned a number of approaches to develop new YF vaccine strategies [ 6 , 16 ]. These include production of the live attenuated vaccine in Vero cells (ClinicalTrials.gov Identifier: NCT04142086), a beta-propiolactone inactivated YF vaccine [ 17 , 18 ] (ClinicalTrials.gov Identifier: NCT00995865), a Modified Vaccinia Ankara vectored recombinant YF vaccine [ 19 ] (ClinicalTrials.gov Identifier: NCT02743455) and (at a preclinical stage) a virus-like particle (VLP) YF vaccine manufactured in transfected HEK293 cells [ 20 ].…”

Section: Introductionmentioning

confidence: 99%

A Yellow Fever Virus 17D Infection and Disease Mouse Model Used to Evaluate a Chimeric Binjari-Yellow Fever Virus Vaccine

et al. 2020

View full text Add to dashboard Cite

Despite the availability of an effective, live attenuated yellow fever virus (YFV) vaccine (YFV 17D), this flavivirus still causes up to ≈60,000 deaths annually. A number of new approaches are seeking to address vaccine supply issues and improve safety for the immunocompromised vaccine recipients. Herein we describe an adult female IFNAR-/- mouse model of YFV 17D infection and disease that recapitulates many features of infection and disease in humans. We used this model to evaluate a new YFV vaccine that is based on a recently described chimeric Binjari virus (BinJV) vaccine technology. BinJV is an insect-specific flavivirus and the chimeric YFV vaccine (BinJ/YFV-prME) was generated by replacing the prME genes of BinJV with the prME genes of YFV 17D. Such BinJV chimeras retain their ability to replicate to high titers in C6/36 mosquito cells (allowing vaccine production), but are unable to replicate in vertebrate cells. Vaccination with adjuvanted BinJ/YFV-prME induced neutralizing antibodies and protected mice against infection, weight loss and liver pathology after YFV 17D challenge.

show abstract

Disease Resurgence, Production Capability Issues and Safety Concerns in the Context of an Aging Population: Is There a Need for a New Yellow Fever Vaccine?

Cited by 15 publications

References 119 publications

Retracted: Deceptology in cancer and vaccine sciences: Seeds of immune destruction‐mini electric shocks in mitochondria: Neuroplasticity‐electrobiology of response profiles and increased induced diseases in four generations – A hypothesis

Retracted: Deceptology in cancer and vaccine sciences: Seeds of immune destruction‐mini electric shocks in mitochondria: Neuroplasticity‐electrobiology of response profiles and increased induced diseases in four generations – A hypothesis

Activation of an Effective Immune Response after Yellow Fever Vaccination Is Associated with the Genetic Background and Early Response of IFN-γ and CLEC5A

A Yellow Fever Virus 17D Infection and Disease Mouse Model Used to Evaluate a Chimeric Binjari-Yellow Fever Virus Vaccine

Contact Info

Product

Resources

About